Drugs that were investigated as potential COVID-19 treatments, such as hydroxychloroquine and favipiravir, have been shown to inhibit Panx1 activity without affecting its gene or protein expression, highlighting their potential to modulate inflammation without interfering with other physiological functions of Panx1 (67). The gene discussed is PANX1; the disease is COVID-19.